Celbopag 25mg Tablet
Rx RequiredSalt Composition: Eltrombopag Olamine
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
7 Tablets of a Strip
About The Product
Hepatitis C, Hepatitis Medicines, Low Red Platelet Count
Description
Celbopag 25mg tablet is a prescription based medication is used in the treatment of hepatitis C and manage low platelet count. It helps manage the infection and supports liver health as part of a prescribed therapy.
Its active ingredient is Eltrombopag Olamine and belongs to the drug class of thrombopoietin receptor agonists (TPO-RAs).
The medicine works by stimulating the production of platelets in the bone marrow, helping to increase low platelets in patients with hepatitis C. Doctor provide this medication under strict guidelines to ensure safety and effectiveness of the medication.
Indication
- Treat hepatitis C and manage low platelet count
Common Side Effects
Celbopag 25mg tablet caused acute and severe side effects but it can be managed with proper treatment. Here are some common side effects, consult the doctor if any of these symptoms persist:
- Common cold
- Cough
- Respiratory tract infection
- Back pain
- High temperature, cough
- Loss of appetite
- Hair loss
- Swelling in feet or hands
- Headache, dizziness
- Mouth and throat pain
- Joint pain
- Diarrhea, abdominal pain
- Common cold
Dosage And Duration
- Celbopag 25mg tablet should be taken on an empty stomach. Doctor's prescription is much needed while using the medicine. The medicine should be swallowed whole, do not chew or crush the tablet as it may reduce the effectiveness of the medication.
- The correct dosage and duration is administered by a healthcare professional. Follow the doctor's guidance as recommended for safety purposes.
Mechanism Of Action
- Celbopag 25mg tablet contains Thrombopoietin receptor agonists belongs to the drug class. It helps to increase the platelets and works as natural hormone thromobopoietin. It stimulates the bone marrow to produce more platelets.
- It is commonly prescribed for conditions where platelet counts are low, such as chronic immune thromobocytopenia (ITP). It helps reduce the risk of bleeding and improve overall platelet in patients with requiring long-term management.
Safety Advice
It is unknown whether it is safe or unsafe but consuming alcohol while taking Celbopag 25mg tablet should be discussed with the doctor.
Celbopag 25mg tablet may cause dizziness and fatigue, avoid taking the medication while you are on driving.
Pregnant women should avoid using Celbopag 25mg tablet as it may affect the new born baby. Consult with the healthcare professional for more query.
Celbopag 25mg tablet should not be recommended to breast feeding women because the medicine is passed through breast milk which harm the new infant.
It is unknown whether Celbopag 25mg tablet cause side effects on kidney function. It is necessary to consult with the doctor if you are a patient with kidney cancer.
Celbopag 25mg tablet is not recommended for liver patients as the medication disrupts the liver function. For more information consult with the healthcare professional.
Faqs
Celbopag 25mg tablet is an anti-cancer medication is used in the treatment of hepatitis C and manage low platelet count.
It helps increase the blood platelet levels, allowing patients to continue antiviral therapy safely and reducing the risk of bleeding.
References
- Dandabattina, R., Subramanian, V. B., Merugu, K. S., SharathBabu, H., Katari, N. K., & Kowtharapu, L. P. (2023). Stability-indicating RP-HPLC method development and validation for eltrombopag olamine in the presence of impurities and degradation products. Robustness by design of expert software. Journal of AOAC International, 106(2), 267-275. https://pubmed.ncbi.nlm.nih.gov/36416121/
- Ganorkar, S. B., Bobade, P. S., Prabhu, R. C., Lokwani, D. K., Shinde, R. N., Telange, D. R., ... & Vander Heyden, Y. (2024). Extension of impurity profiling on eltrombopag olamine to in-silico predictions: An effort to exploit correlated forced degradation products and known drug-related substances in drug discovery. Journal of Chromatography B, 1248, 124367. https://pubmed.ncbi.nlm.nih.gov/39547062/
- Jayagopal, B., & Murugesh, S. (2021). QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity prediction. Journal of Pharmaceutical and Biomedical Analysis, 203, 114231. https://pubmed.ncbi.nlm.nih.gov/34225039/
- Kaduk, J. A., Gindhart, A. M., & Blanton, T. N. (2021). Crystal structure of eltrombopag olamine form I,(C2H8NO) 2 (C25H20N4O4). Powder Diffraction, 36(2), 100-106.
- Patel, A. I., Gosaı, S., Jadav, K., Vyas, A. J., Patel, A. B., & Patel, N. K. (2020). Stability indicating analytical method development and validation of eltrombopag olamine in tablet dosage form by RP-UPLC. Journal of the Turkish Chemical Society Section A: Chemistry, 7(3), 845-850.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
